Overview

Romiplostim in Treating Hepatitis C-Infected Patients With Thrombocytopenia

Status:
Terminated
Trial end date:
2018-07-14
Target enrollment:
Participant gender:
Summary
RATIONALE: Romiplostim may cause the body to make platelets. PURPOSE: This randomized phase II trial is studying how well romiplostim works in treating hepatitis C-infected patients with thrombocytopenia.
Phase:
Phase 2
Details
Lead Sponsor:
University of Southern California
Treatments:
Interferon alpha-2
Interferon-alpha
Interferons
Peginterferon alfa-2a
Ribavirin